A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms PROMIS II
- Sponsors Zambon SpA
- 14 Feb 2019 Planned number of patients changed from 374 to 420.
- 14 Feb 2019 Planned End Date changed from 1 Mar 2021 to 1 Jul 2020.
- 14 Feb 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Jul 2020.